Cell signaling news
Here we present recent news items specially selected from Nature, Nature Medicine and Nature Biotechnology.
December 2004
2004:
December |
November |
October |
September |
August |
July |
June |
May |
April |
March |
February |
January
Other years: 2003 | 2004 | 2005 | 2006 | 2007 | 2008
News | News in brief | News Features
News
Activists and researchers rally behind AIDS drug for mothers
The drug, nevirapine, is used to help prevent mother-to-baby transmission of HIV, but stories published by the Associated Press earlier this month re-ignited controversy in Africa over whether nevirapine is safe and effective.
Nature (23 December 2004)
| Full Text |
Funding review sparks fears for Canadian science
Canadian scientists are anxiously awaiting the results of a government spending review, amid fears that it could reverse the recent spurt in federal support for research.
Nature (23 December 2004)
| Full Text |
Tempers flare over plan to move Pasteur labs
Scientists at the Pasteur Institute in central Paris are protesting over plans to relocate part of the prestigious research center to a commercial zone on the outskirts of the city.
Nature (16 December 2004)
| Full Text |
Relaxed rules open path to genomic data on disease
To the delight of researchers mining the human genome for disease-related genes, restrictions on the use of data from the International HapMap Project were dropped last week, and the information can now be incorporated into other databases.
Nature (16 December 2004)
| Full Text |
Californians hash out guide for spending stem-cell billions
The authors of California's plan to spend $3 billion on human embryonic stem-cell research met this week to work out how the money should be distributed.
Nature (9 December 2004)
| Full Text |
Thompson cedes crown after stormy reign over US health
With the resignation of Tommy Thompson, who has served as US health secretary since 2001, life scientists in the United States say they hope their sometimes fraught relationship with the government will improve.
Nature (9 December 2004)
| Full Text |
Inquiry hears claim of threats over lab move
Some of Britain's most eminent academics are embroiled in an unseemly public squabble over plans to relocate the NIMR, a prestigious London research institute.
Nature (9 December 2004)
| Full Text |
Scientists turn anxious eyes to Bush's second term
With George W. Bush about to embark on a second term in office, researchers who had pinned their hopes on Democratic challenger John Kerry are feeling stunned.
Nature Medicine (December 2004)
| Full Text |
Scientists divided on relevance of race in medical research
The controversy that surrounds BiDil – the first drug marketed to a specific racial group – illustrates that, among scientists, there is little consensus on the usefulness of race in genetic studies.
Nature Medicine (December 2004)
| Full Text |
UK criticized for embryo screening decision
The UK's Human Fertilisation and Embryology Authority (HFEA) has come under fire for allowing, for the first time in Britain, genetic screening of embryos for a disease that will not affect the child at birth.
Nature Medicine (December 2004)
| Full Text |
New technologies deliver in treating neurological diseases
New techniques that use RNA interference (RNAi) and osmotic pumps to deliver medicines are moving to clinical trials after proving successful in animal models of amyotrophic lateral sclerosis (ALS).
Nature Medicine (December 2004)
| Full Text |
Despite snags and skepticism, Thai vaccine trial lumbers on
The US Food and Drug Administration (FDA) may not license for use in the US an AIDS vaccine now in large-scale trials in Thailand because it has "a relatively low level of efficacy," the agency says.
Nature Medicine (December 2004)
| Full Text |
Immune response to SARS sets up puzzling paradox
Scientists are still baffled by how SARS, which claimed nearly 800 lives last year, affects the immune system.
Nature Medicine (December 2004)
| Full Text |
HIV vaccine research a shot in the arm for immunologists
Decades of research have failed to produce a slam-dunk AIDS vaccine, but the fruitless efforts have proven a boon for basic immunologists, adding new tools and knowledge to their repertoire.
Nature Medicine (December 2004)
| Full Text |
Next generation flu vaccine boosted by Chiron debacle
More innovative solutions in flu vaccine production could prevent another flu vaccine shortage in the future.
Nature Biotechnology (December 2004)
| Full Text |
FDA and EMEA pool scientific advice
Biotech companies could have their say in setting up standards for regulatory approval of cutting edge drugs, as they benefit from parallel scientific advice from Europe and the US.
Nature Biotechnology (December 2004)
| Full Text |
Suppressed study raises spectre of flawed drug regulation in US
Amid claims that it suppressed publication of a study into the safety of a painkiller, the US Food and Drug Administration (FDA) is under increasing pressure to reform the way in which it monitors approved drugs.
Nature (02 December 2004)
| Full Text |
Croats protest that science minister is 'meddling' in MedILS
Croatian scientists are up in arms over possible government interference in plans for the Mediterranean Institute for Life Sciences (MedILS), a world-class research institute on the Adriatic coast.
Nature (02 December 2004)
| Full Text |
Geneticists prepare for deluge of mutant mice
Medical researchers will soon be able to select their perfect mouse model from a catalogue of mutants covering every single gene, specialists say.
Nature (02 December 2004)
| Full Text |
News in brief
Hungarian head named for launch of 'European CDC'
| Painkiller trial halted over heart scare
| US company buys into China's biotech market
| Europe's biology club gives Iceland a warm welcome
| Google finds itself in court in trademark row
| UK to relax tax stranglehold on enterprising academics
| Europeans rewarded with Descartes prizes
| Row over axed courses hits UK government
| Generics manufacturer withdraws AIDS drugs
| FDA set to overhaul drug safety, marketing
| Spain loosens reins on stem cell research
| Malaria drugs in short supply
| Swiss voters give emphatic thumbs-up to stem-cell research
News Features
All I want for 2005 is...
Nature highlights some of the events that excited the world of science over the past 12 months and is also making some enquiries into what scientists think – and hope – is in store next.
Nature (23 December 2004)
| Full Text |
Islamic science: Rebuilding the past
Western science owes much to Islam's golden age — a debt that is often forgotten. To help redress the balance, Fuat Sezgin has reconstructed a host of scientific treasures using ancient Arabic texts. Alison Abbott reports.
Nature (16 December 2004)
| Full Text |
Religion and science: Studies of faith
Embryonic stem-cell research is putting fresh strain on the already fractious relationship between science and religion. Tony Reichhardt explores how faith is shaping the ever-changing landscape of bioethics.
Nature (9 December 2004)
| Full Text |
Religion and Science: Buddhism on the brain
Many religious leaders find themselves at odds with science, but the head of Tibetan Buddhism is a notable exception. Jonathan Knight meets a neurologist whose audience with the Dalai Lama helped to explain why.
Nature (9 December 2004)
| Full Text |
The worm has turned
For decades, scientists have struggled to stem the spiking rates of asthma. Could the key to a cure be a belly full of writhing worms? Charlotte Schubert investigates.
Nature Medicine (December 2004)
| Full Text |
Can China bring its own pipeline to the market?
China is a growing biotech player whose main competitive edge lies in low development costs. But will inexperienced money men and a disinterested pharmaceutical industry hold it back? Sabine Louët investigates.
Nature Biotechnology (December 2004)
| Full Text |
Data page: The biotech drug market
In recent years, biotech has claimed an increasing share of novel treatments approved by the US Food and Drug Administration; that trend will shift this year.
Nature Biotechnology (December 2004)
| Full Text |
Dispatches from the front line
Bad news travels fastest. Or so the scientists fighting disease hope. Since 1994, ProMED-mail has been reporting outbreaks as soon as they happen. Erika Check meets the team behind the 24-hour service.
Nature (02 December 2004)
| Full Text |
David versus Goliath
Resources are shifting from small labs led by one researcher to large teams with expensive equipment. But has the rise of big biology gone too far? Erika Check investigates.
Nature (02 December 2004)
| Full Text |
|
